Salud reinforces the use of artificial intelligence in diagnostics and treatments

email Servicio Navarro de Salud-Osasunbidea refuerza su apuesta por la utilizado de artificial intelligence en la atención sanitaria, con varias initiativas para el tratamiento y diagnostico de enfermedades. The most immediate implantation of this technology in the Service Navarro de Salud-Osasunbidea will be for the treatment of it Degeneración Macular Asociada a la Edad (DMAE), que se suma a la ya existente para el diagnostico de la Diabetic retinopathyand that will have continuity in the future in other applications related to it Dermatology and Radiology.

El desarrollo de estas aplicaciones se realiza por personal técnico del Servicio de Tecnologías de la Salud from the General Directorate of Telecommunications and Digitalization, in collaboration with the Subdirección de Sistemas de Información del SNS-O and the clinical services involved.

The application NaIA-DMAEwhose launch is scheduled for the first trimester of 2023, will allow, through the use of artificial intelligence in Age-Associated Macular Degeneration, to predict the evolution of this disease in each patient, making it possible to personalize the treatment more adecuado a cada caso con un considerable ahorro de tiempo.

Likewise, it is expected that this technological strategy will have continuity in other programs that also involve artificial intelligence in health, such as NaIA Dermatology and NaIA Bone Radiology, in aspects very related to collaboration circuits between Primary and Hospital Attention, with a high potential for diminuir derivaciones de pacientes y por lo tanto, listas de espera. Estos proyectos se unen así al programa NaIA-Retinopatía Diabética, en funcionamiento desde 2020, y cuyos resultados proparicaron recentente al SNS-O una distinción nacional de gestion sanitaria.

The use of artificial intelligence as an auxiliary tool for making clinical decisions is one of the objectives of the II Days of Innovation, Evaluation and Diffusion of Results in Health, which, under the motto Recopilando el conocimiento, are celebrated at the University Hospital de Navarre. The first session was on the 21st and the second session will be on the 28th, in which the evaluation of results in clinical practice, the use of analytical accounting for decision-making and research and advanced statistical analysis will be discussed.

Causa de pérdida visual

La Degeneración Macular Asociada a la Edad (DMAE) is the most important cause of irreversible visual loss in the elderly population in Navarre and constitutes the main reason for citation from the Ophthalmology Service. The volume of patients increases every time due to the aging of the population.

En cada consulta sobre esta dolencia, al paciente se le mide la agudeza visual y se le realiza una Tomografía de Hererencia Óptica, prueba formeda por 50 imágenes, 25 por cada ojo. El oftalmólogo debe valorar a contidação la tomografía de ese día y revisar las previouses para decidir si procede una nueva dosis del pharmaco para tratar esta dolencia, que se administra mediate una injección en la retina, y programar una nueva visita. Given the limited time of the consultation, it is very complicated to value the revision of all the previous tests, so the decision on the administration of the drug tends to be based on the evolution of the most recent ones.

LaIA-DMAE analyzes all tomographies and generates a series of measurements (known as biomarkers) on harmful liquids present in the retina, which are stored in the Historia Clínica Informatizada (HCI). Through the use of these biomarkers, HCI generates a graph that represents the response to treatment in each patient.

This information, available at the same moment of consultation, allows for better informed decisions, much faster and more objective, based on measurements.

.

Leave a Comment

Your email address will not be published. Required fields are marked *